COGT · Company research
Cogent Biosciences, Inc. Common Stock (COGT): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
18records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Technical Reactions to COGT Trends in Macro Strategies - Stock Traders Daily | Technical Reactions to COGT Trends in Macro Strategies Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 15, 2026 | neutral | 0 | 0.6 |
| Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years - Benzinga | Here’s How Much You Would Have Made Owning Cogent Biosciences Stock In The Last 5 Years Benzinga | View source ↗ | Benzinga | Oct 12, 2026 | neutral | 0 | 0.6 |
| Fidelity Small Cap Growth K6 Fund's Cogent Biosciences Inc(COGT) Holding History - GuruFocus | Fidelity Small Cap Growth K6 Fund's Cogent Biosciences Inc(COGT) Holding History GuruFocus | View source ↗ | GuruFocus | Oct 10, 2026 | neutral | 0 | 0.6 |
| Cogent Biosciences Inc. Stock Grades | COGT - Barron's | Cogent Biosciences Inc. Stock Grades | COGT Barron's | View source ↗ | Barron's | Oct 9, 2026 | neutral | 0 | 0.6 |
| Taking options instead of cash, a Cogent Biosciences (COGT) director receives a 759-option award. - Stock Titan | Taking options instead of cash, a Cogent Biosciences (COGT) director receives a 759-option award. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| $1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today - Benzinga | $1000 Invested In Cogent Biosciences 5 Years Ago Would Be Worth This Much Today Benzinga | View source ↗ | Benzinga | Oct 2, 2026 | neutral | 0 | 0.6 |
| Cogent Biosciences Inc (COGT-Q) Stock Price and News - The Globe and Mail | Cogent Biosciences Inc (COGT-Q) Stock Price and News The Globe and Mail | View source ↗ | The Globe and Mail | Oct 1, 2026 | neutral | 0 | 0.6 |
| Should FDA Filing Acceptance Require Action From Cogent Biosciences (COGT) Investors? - Simply Wall Street | Should FDA Filing Acceptance Require Action From Cogent Biosciences (COGT) Investors? Simply Wall Street | View source ↗ | Simply Wall Street | Sep 26, 2026 | neutral | 0 | 0.6 |
| Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA - Yahoo Finance | Cogent Biosciences (COGT) Stock Trades At A Premium As FDA Accepts NDA Yahoo Finance | View source ↗ | Yahoo Finance | Sep 25, 2026 | neutral | 0 | 0.6 |
| Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat (NASDAQ:COGT) - Seeking Alpha | Cogent Biosciences: 3 NDAs Create A Time-To-Market Moat (NASDAQ:COGT) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 27, 2026 | neutral | 0 | 0.6 |
| Cogent Biosciences (NASDAQ: COGT) director schedules option-led stock sale years ahead - Stock Titan | Cogent Biosciences (NASDAQ: COGT) director schedules option-led stock sale years ahead Stock Titan | View source ↗ | Stock Titan | Aug 27, 2026 | neutral | 0 | 0.6 |
| Cogent’s Bezuclastinib Could Reach FDA Decisions in Nov., Dec. - Stock Titan | Cogent’s Bezuclastinib Could Reach FDA Decisions in Nov., Dec. Stock Titan | View source ↗ | Stock Titan | Aug 10, 2026 | neutral | 0 | 0.6 |
| Cogent Biosciences Gains as Investors Revisit Late-Stage Bezuclastinib Catalysts | COGT Stock News - Quiver Quantitative | Cogent Biosciences Gains as Investors Revisit Late-Stage Bezuclastinib Catalysts | COGT Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 4, 2026 | neutral | 0 | 0.6 |
| COGT Forecast — Price Target — Prediction for 2027 - TradingView | COGT Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 26, 2026 | neutral | 0 | 0.6 |
| Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT) - Seeking Alpha | Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage (NASDAQ:COGT) Seeking Alpha | View source ↗ | Seeking Alpha | Jun 14, 2026 | neutral | 0 | 0.6 |
| Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now? - Yahoo Finance | Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 7, 2026 | neutral | 0 | 0.6 |
| Cogent Biosciences Inc (NASDAQ:COGT) Shows Bullish Technical Breakout Setup with High Scores - ChartMill | Cogent Biosciences Inc (NASDAQ:COGT) Shows Bullish Technical Breakout Setup with High Scores ChartMill | View source ↗ | ChartMill | May 2, 2026 | neutral | 0 | 0.6 |
| Fairmount funds sells Cogent Biosciences (COGT) shares for $242.6m - Investing.com | Fairmount funds sells Cogent Biosciences (COGT) shares for $242.6m Investing.com | View source ↗ | Investing.com | Mar 31, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.